List of Elyxyb drug patents

Elyxyb is owned by Bdsi.

Elyxyb contains Celecoxib.

Elyxyb has a total of 6 drug patents out of which 0 drug patents have expired.

Elyxyb was authorised for market use on 05 May, 2020.

Elyxyb is available in solution;oral dosage forms.

Elyxyb can be used as acute treatment of migraine with or without aura in adults.

The generics of Elyxyb are possible to be released after 27 May, 2036.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10722456 BDSI Oral composition of celecoxib for treatment of pain
May, 2036

(13 years from now)

US10799517 BDSI Oral composition of celecoxib for treatment of pain
May, 2036

(13 years from now)

US9949990 BDSI Oral composition of celecoxib for treatment of pain
May, 2036

(13 years from now)

US9795620 BDSI Oral composition of celecoxib for treatment of pain
May, 2036

(13 years from now)

US9572819 BDSI Oral composition of celecoxib for treatment of pain
May, 2036

(13 years from now)

US10376527 BDSI Oral composition of celecoxib for treatment of pain
May, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) May 5, 2023

Drugs and Companies using CELECOXIB ingredient

Market Authorisation Date: 05 May, 2020

Treatment: Acute treatment of migraine with or without aura in adults

Dosage: SOLUTION;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in